

BrainCool AB (publ): Upcoming scientific publication for BrainCool regarding NeuroChill shows statistically significant results

BrainCool conducts development and clinical studies relating to cooling treatment combined with thrombectomy in collaboration with the University Hospital in Freiburg, financed with a grant of approximately 3 million Euro. Two clinical studies (Cottis 1 and 2) are planned within the EU program.

· The Cottis-1 study (1) has been accepted for publication in the highly regarded scientific journal 'Stroke & Vascular Neurology' (with an impact factor of 10, 2023). The journal has announced that it will publish the article in the September issue or present it online within a couple of weeks.

· Furthermore, the Cottis-2 study (2), a randomized study of 400 patients, has recently received granted ethical approval, planning to start after summer. In addition, the University Hospital in Freiburg has completed a new scientific article based on the data generated through discussions with BrainCool and the FDA.

New clinical data with significant results

This forthcoming scientific publication is based on a so-called "matched-pair-analysis" performed on 650 patients (3), who during the period 2016-2021 were treated with thrombectomy, at the University Hospital in Freiburg.

At a group meeting for the Cottis-2 study, the results have been shared with a larger circle of people, which is why BrainCool now decides to share the results with the market.

The results from the feasibility study with 22 patients who underwent treatment with cooling therapy, have been compared with 44 patients with the same age, gender and the same type of brain damage (1).

A shift analysis shows statistically significant results ($p < 0.05$) with an increased stroke survival after three months of follow-up, **from 34.2% to 68.2%**, with a good neurological function (mRS 0-2).

CEO Martin Waleij comments:

Of course, the shift analysis does not replace the randomized trial. However, we can conclude that additional scientific publications strengthen our hypothesis. In fact, we can now show that Neurochill delivers the desired effect; chance is "eliminated".

If the above results are generalized to a randomized trial, significance would already be obtained after 52 – 56 patients.

References

1. [MFN.se > BrainCool > Publication Acceptance of BrainCool's Thrombectomy Study in Stroke & Vascular Neurology](#)

2. [MFN.se > BrainCool > BrainCool AB \(publ\): Ethical approval for the clinical study for stroke patients](#)
3. Matching was performed for patients previously treated in Freiburg (2016-2021) based on their **age, NIHSS on admission, ASPECTS score on admission, and location of large vessel occlusion**

Contacts**For more information**

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

This information is information that BrainCool is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-09 08:20 CEST.

Attachments

[BrainCool AB \(publ\): Upcoming scientific publication for BrainCool regarding NeuroChill shows statistically significant results](#)